TY - JOUR
T1 - A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-Term usage of oxaliplatin
AU - Ito, Isao
AU - Ito, Yasuhiko
AU - Mizuno, Masashi
AU - Suzuki, Yasuhiro
AU - Yasuda, Kaoru
AU - Ozaki, Takenori
AU - Kosugi, Tomoki
AU - Yasuda, Yoshinari
AU - Sato, Waichi
AU - Tsuboi, Naotake
AU - Maruyama, Shoichi
AU - Imai, Enyu
AU - Matsuo, Seiichi
PY - 2012/6
Y1 - 2012/6
N2 - Oxaliplatin is effective in advanced colorectal cancer and is known to have relatively few side effects, such as hemolysis and renal toxicity. We report a case of acute kidney injury (AKI) after treatment with a combination of oxaliplatin, folinic acid and 5-fluorouracil or capecitabine. The patient developed acute renal failure, hemolytic anemia and thrombocytopenia after the 34th course of chemotherapy including oxaliplatin. A positive direct antiglobulin test and detection of immunoglobulin G and complement C3b and C3d on erythrocytes suggested the diagnosis of immune-related severe intravascular hemolytic anemia. She was successfully treated and recovered using plasma exchange, corticosteroids and hemodialysis therapy. Only seven other cases of AKI associated with oxaliplatin use have been reported to date. As in this case, acute hemolysis due to autoimmune mechanisms and subsequent AKI occurred suddenly after frequent use of oxaliplatin in four of those cases. We should be aware that oxaliplatin may cause sudden life-Threatening hemolysis by drug-induced antibodies and subsequent AKI, even though oxaliplatin is frequently administered without side effects. This represents the first case report of AKIrelated hemolysis due to oxaliplatin in Japan.
AB - Oxaliplatin is effective in advanced colorectal cancer and is known to have relatively few side effects, such as hemolysis and renal toxicity. We report a case of acute kidney injury (AKI) after treatment with a combination of oxaliplatin, folinic acid and 5-fluorouracil or capecitabine. The patient developed acute renal failure, hemolytic anemia and thrombocytopenia after the 34th course of chemotherapy including oxaliplatin. A positive direct antiglobulin test and detection of immunoglobulin G and complement C3b and C3d on erythrocytes suggested the diagnosis of immune-related severe intravascular hemolytic anemia. She was successfully treated and recovered using plasma exchange, corticosteroids and hemodialysis therapy. Only seven other cases of AKI associated with oxaliplatin use have been reported to date. As in this case, acute hemolysis due to autoimmune mechanisms and subsequent AKI occurred suddenly after frequent use of oxaliplatin in four of those cases. We should be aware that oxaliplatin may cause sudden life-Threatening hemolysis by drug-induced antibodies and subsequent AKI, even though oxaliplatin is frequently administered without side effects. This represents the first case report of AKIrelated hemolysis due to oxaliplatin in Japan.
UR - http://www.scopus.com/inward/record.url?scp=84863716268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863716268&partnerID=8YFLogxK
U2 - 10.1007/s10157-012-0620-8
DO - 10.1007/s10157-012-0620-8
M3 - Article
C2 - 22450906
AN - SCOPUS:84863716268
SN - 1342-1751
VL - 16
SP - 490
EP - 494
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 3
ER -